For research use only
| Cat No. | ABL-TC0580 |
| Product Type | Human Lymphoma Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peritoneal Effusion |
| Disease | Malignant Lymphoma |
| Product Code | RCK-8; RCK8; Rck8 |
Advance RC-K8 Cell Line applications in lymphoma research, focusing on t(11;14) chromosomal translocation, lymphoid morphology, and oncogenic pathways.
RC-K8 is a human lymphoma cell line derived from peritoneal effusion of a histiocytic lymphoma patient The cells grow mainly in suspension with pleomorphic morphology. Cytochemical assays show positivity for alpha-naphthyl butyrate esterase, acid phosphatase, and periodic acid–Schiff, indicating their unique biochemical profile. Immunophenotyping demonstrates reactivity to B cell markers (B1, Leu12) and MHC class II (OKIa1), confirming B-lineage origin. The cell line exhibits immunoglobulin gene rearrangement but lacks surface and cytoplasmic immunoglobulin expression. Cytogenetic analysis reveals complex abnormalities, including a characteristic t(11;14) translocation. RC-K8 serves as a valuable in vitro model for investigating B cell malignancies, chromosomal rearrangements in lymphomagenesis, and immunoglobulin gene regulation in atypical lymphoid cells.
| Product Code | RCK-8; RCK8; Rck8 |
| Species | Human |
| Cat.No | ABL-TC0580 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peritoneal Effusion |
| Disease | Malignant Lymphoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lymphoma Cell Lines |
The RC-K8 Cell Line is invaluable for studying lymphomagenesis and pulmonary metastasis in lymphoma. It serves as a model for investigating the antitumor effects of potential drugs, particularly those targeting B-cell lymphoma. Researchers utilize RC-K8 to explore immunotherapy strategies for lymphoma, focusing on key enzymes involved in immune evasion. Additionally, this cell line is pivotal in drug discovery, aiding in the evaluation of novel compounds’ antitumor activity and elucidating their molecular mechanisms against hematopoietic malignancies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
